logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharmaceuticals to build on success of 'extremely exciting' 2016

Dr Markku Jalkanen, chief executive,  talks about the "very good" 2016 for the firm, its first full year on AIM, in which it advanced its pipeline, and continued to advance lead drug Traumakine.
The biotech is now gearing up for the completion of a final phase clinical trial of its lead product later this year.
"We pretty much did what we promised to do in the IPO," he told Proactive's Andrew Scott.

Quick facts: Faron Pharmaceuticals Ltd

Price: 422.5 GBX

AIM:FARN
Market: AIM
Market Cap: £197.73 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine...

Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products. Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment...

on 21/2/18

2 min read